<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="issn">2168-8184</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus</publisher-name><publisher-loc>Palo Alto (CA)</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38125244</article-id><article-id pub-id-type="pmc">PMC10732334</article-id><article-id pub-id-type="doi">10.7759/cureus.49121</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pathology</subject></subj-group><subj-group><subject>Cardiology</subject></subj-group><subj-group><subject>Therapeutics</subject></subj-group></article-categories><title-group><article-title>Familial Hypercholesterolemia: A Literature Review of the Pathophysiology and Current and Novel Treatments</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Muacevic</surname><given-names>Alexander</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Adler</surname><given-names>John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Suryawanshi</surname><given-names>Yasha N</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Warbhe</surname><given-names>Rupesh A</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Department of Physiology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND </aff><aff id="aff-2">
<label>2</label>
Department of Pharmacology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND </aff><author-notes><corresp id="cor1">
Yasha N. Suryawanshi <email>yashasuryawanshi550@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>11</month><year>2023</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>11</month><year>2023</year></pub-date><volume>15</volume><issue>11</issue><elocation-id>e49121</elocation-id><history><date date-type="received"><day>24</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2023, Suryawanshi et al.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Suryawanshi et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xlink:href="https://www.cureus.com/articles/185978-familial-hypercholesterolemia-a-literature-review-of-the-pathophysiology-and-current-and-novel-treatments">This article is available from https://www.cureus.com/articles/185978-familial-hypercholesterolemia-a-literature-review-of-the-pathophysiology-and-current-and-novel-treatments</self-uri><abstract><p>Familial hypercholesterolemia (FH) is a genetically transmitted disorder. It shows an autosomal dominant mode of inheritance. It is a metabolic disorder. Mutation in chromosome 19 leads to this disorder. Chromosome 19 codes data for low-density lipoprotein (LDL) receptor (LDLR). LDLR either reduces increased LDL levels from the circulation or maintains a normal level of LDL. It precipitates the risk of cardiovascular disease at an early age. Characteristic features of FH are elevated levels of LDL in the blood because of sudden changes in LDLR, which causes a decrease in the clearance of LDL from the blood. Plaque gets deposited in the lumen of the arteries, called atherosclerosis, which occurs at an early young age. If both genes are affected then it is homozygous FH (HoFH); such a case is very rare. When a single gene is affected then that condition is known as heterozygous FH (HeFH). HoFH comes up with more severe cardiac disease than HeFH at an early age. The major cause of FH is a mutation in the LDLR gene while other causes include mutation in various genes like apolipoprotein B (apo B), proprotein convertase subtilisin/kexin type 9 (PCSK9), LDLR adaptor protein 1 (LDLRAP 1). In order to prevent cardiovascular crises due to FH, it must be diagnosed early and treated effectively. With increasing research and advances in medical sciences, many kinds of current and novel therapies are emerging that aim to reduce the level of LDL in blood.</p></abstract><kwd-group kwd-group-type="author"><kwd>heterozygous familial hypercholesterolemia</kwd><kwd>homozygous familial hypercholesterolemia</kwd><kwd>low density lipoprotein-cholesterol</kwd><kwd>novel therapeutics</kwd><kwd>current therapeutics</kwd><kwd>pathophysiology of familial hypercholesterolemia</kwd><kwd>familial hypercholestrolemia</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction and background</title><p>Familial hypercholesterolemia (FH) is a gene-related metabolic disorder. This autosomal dominant disease is defined as significantly raised low-density lipoprotein (LDL) cholesterol levels since birth, leading to the increased risk of cardiac manifestation at a young age, which can be fatal [<xref rid="REF1" ref-type="bibr">1</xref>]. In general, the occurrence of FH in unselected general populations has been assessed to be one in 200-250 in heterozygous FH (HeFH) and one in 160,000-300,000 in homozygous FH (HoFH). This indicates most inherited hereditary disorders in human beings may be FH [<xref rid="REF1" ref-type="bibr">1</xref>]. The mutated gene responsible for FH is located on chromosome 19. This chromosome 19 carries information regarding a protein called LDL receptor (LDLR), and it removes LDL cholesterol from circulation. One in 500 people has an affected gene that causes FH. If only one allele is affected, then it is known as HeFH, and if a person inherits the gene alteration from both parents, it is called HoFH. HoFH is a significantly major form of hypercholesterolemia, with the occurrence of cardiovascular disease (CVD) and demise at an early age [<xref rid="REF2" ref-type="bibr">2</xref>].</p><p>FH exposes people to high LDL cholesterol levels for the rest of their lives. It is not uncommon, but it is often underdiagnosed. Though there are treatments for FH, it is not treated properly. Preliminary detection and management reduce an increased premature CVD resulting from FH [<xref rid="REF3" ref-type="bibr">3</xref>]. This disorder is detected by clinical characteristics, ancestral history, and raised LDL levels, which have currently been supported by gene-based therapeutics. Early identification and treatment are essential since the degree and scope of contact with LDL cholesterol levels dictate atherosclerotic stress. Though new drugs, LDL apheresis, and other investigational treatments may be helpful for some hard-to-treat subsets of FH, statins are most commonly prescribed and are important treatments for these patients. Collectively, these new emerging therapies have significantly enhanced the outcome of FH, particularly in heterozygous individuals [<xref rid="REF4" ref-type="bibr">4</xref>].</p><p>Many FH patients require multiple medications to achieve optimal LDL cholesterol lowering. According to LDL levels and how they respond to treatment, patients might need multiple medications. Ezetimibe, bile-acid sequestrants, and niacin are among the drugs that can be combined with statins to reduce LDL cholesterol [<xref rid="REF3" ref-type="bibr">3</xref>]. LDL apheresis, which is nonsurgical therapy, is a significant management choice for both types of FH sufferers who fail to attain their treatment objectives despite receiving optimal tolerated medical therapy. Monoclonal antibodies to PCSK9 are the most highly ensuring recent treatment for FH [<xref rid="REF3" ref-type="bibr">3</xref>]. Nutritional pharmacological substances that are naturally lipid-controlling agents are advised in conjunction with the treatment of hypercholesterolemia. It affects lipid metabolism, enhancing the consequences of various lipid-lowering treatments [<xref rid="REF5" ref-type="bibr">5</xref>]. If left untreated, FH enhances the possibility of CVD. Maintained elevated cholesterol levels promote oxidation of lipoproteins and intrusion through the endothelial hurdle, and hastening atherosclerotic plaque progression [<xref rid="REF5" ref-type="bibr">5</xref>].</p></sec><sec sec-type="review"><title>Review</title><p>Methodology</p><p>We performed a systematic search through PubMed Central in July 2023 using keywords and Medical Subject Headings (MeSH) such as &#x0201c;familial hypercholesterolemia&#x0201d; and &#x0201c;pathophysiology&#x0201d; and &#x0201c;pharmacological therapies&#x0201d; (((familial hypercholesterolemia [Title/Abstract]) OR (novel therapies[Title/Abstract])) OR (pathophysiology*[Title/Abstract])) OR (&#x0201c;Heterozygous familial hypercholesterolemia&#x0201d; [MeSH Terms]) AND ((&#x0201c;Homozygous familial hypercholesterolemia&#x0201d; [Title/Abstract]) OR (Current therapies to treat familial hypercholesterolemia [Title/Abstract])) OR (&#x0201c;Novel therapies to treat familial hypercholesterolemia&#x0201d; [MeSH Terms]). We additionally searched for key references from the bibliographies of the relevant studies. Figure <xref rid="FIG1" ref-type="fig">1</xref> shows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart that was followed.</p><fig position="anchor" fig-type="figure" id="FIG1"><label>Figure 1</label><caption><title>PRISMA flowchart showing the selection process of articles reviewed</title><p>PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis</p></caption><graphic xlink:href="cureus-0015-00000049121-i01" position="float"/></fig><p>Pathophysiology of FH</p><p>FH occurs widely because of mutation in the following genes: LDLR gene, apolipoprotein B (Apo B), proprotein convertase subtilisin/kexin type 9 (PCSK 9), LDLR adaptor protein 1 (LDLRAP1), and other unidentified genes [<xref rid="REF6" ref-type="bibr">6</xref>]. In the body, LDL normally circulates for some time then eventually the Apo B portion in LDL attaches to LDLR on the hepatocytes leading to the uptake of LDL and its digestion [<xref rid="REF7" ref-type="bibr">7</xref>]. LDL is cleared from the circulatory system as a result of this process. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) enzyme synthesizes cholesterol, this enzyme is inhibited resulting in the lowering of cholesterol levels [<xref rid="REF8" ref-type="bibr">8</xref>]. LDL receptor is absent or reduced in FH which leads to the presence of LDL in circulation for 4.5 days causing elevated LDL levels in blood [<xref rid="REF9" ref-type="bibr">9</xref>]. Frequent genetic abnormalities in FH are LDLR loss of functional mutations (among 250 single individuals affected), Apo B functional loss, PCSK9-acquired functional alterations, and LDLRAP alterations [<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>LDL Receptor Gene</p><p>Chromosome 19 has a p arm containing the LDL gene. In about 40% of cases by the age of 50, only one altered gene as in HeFH leads to heart disorder. Having two altered genes as in HoFH causes accelerated heart disorders during the young years of life with severe complications. The action of LDLR among homozygotes is below 2%, but in the case of HeFH having flawed LDL activity with its receptor, it is&#x000a0;2-25%, on the basis of the type of the mutation [<xref rid="REF10" ref-type="bibr">10</xref>]. There are five main classes that depict types of LDLR mutations [<xref rid="REF11" ref-type="bibr">11</xref>]. There is no synthesis of LDLR in class 1 while there is difficulty in the transferring of LDLR from the endoplasmic reticulum to the Golgi apparatus in class 2. In class 3, apo B is defective, which leads to improper binding between LDLR and hepatocyte cells. In class 4, there is a defect in cluster clathrin-coated pits receptor leading to improper endocytosis. In class 5, the recycling of LDLR is hampered.</p><p>Apo B</p><p>Lipoprotein particles consist of a protein part called apolipoprotein B. The gene that codes it, is 46.2 kb in length, located on chromosome 2 (2p24-p23). FH is generally linked with the mutation in R3500Q, leading to a replacement of glutamine for arginine at 3500 places. Binding is improper as there is a structural change in the protein that attaches to the LDLR. The higher the amount of abnormal copies of LDLR, the higher the cholesterol levels [<xref rid="REF12" ref-type="bibr">12</xref>].</p><p>PCSK9</p><p>Familial cholesterolemia also occurs due to mutation in proprotein convertase subtilisin/kexin type 9. Chromosome one carries this gene [<xref rid="REF1" ref-type="bibr">1</xref>].</p><p>LDLRAP 1</p><p>LDLRAP1, also known as ARH (adaptor-related protein homolog), was identified in FH [<xref rid="REF13" ref-type="bibr">13</xref>]. Protein mutations typically result in the production of less protein. Its true mechanism of action is unknown; it may&#x000a0;be involved in the interaction of clathrin-coated pits with LDLRs [<xref rid="REF14" ref-type="bibr">14</xref>]. Table <xref rid="TAB1" ref-type="table">1</xref> depicts genes undergoing mutations in FH, their mechanism of action, and the mutated effects of those genes [<xref rid="REF3" ref-type="bibr">3</xref>].</p><table-wrap position="float" id="TAB1"><label>Table 1</label><caption><title>Genes involved in familial hypercholesterolemia, mutation in those genes, their mechanism of action, mutated effect of the gene</title><p>LDLR: low density lipoprotein receptor; LDL: low density lipoprotein; LDLRAP1: low-density lipoprotein receptor adaptor protein 1; Apo B: apolipoprotein B; PCSK9: proprotein convertase subtilisin/Kexin type 9</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Gene</td><td rowspan="1" colspan="1">Mutation</td><td rowspan="1" colspan="1">Mechanism of action</td><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0; Mutated effect</td></tr><tr><td rowspan="1" colspan="1">LDLR</td><td rowspan="1" colspan="1">LDLR</td><td rowspan="1" colspan="1">LDLR mediates the&#x000a0;endocytosis&#x000a0;of cholesterol-rich LDL and thus maintains the&#x000a0; plasma level of LDL</td><td rowspan="1" colspan="1">LDLR may be absent or decreased leading to increased plasma levels of LDL</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">LDLRAP1</td><td rowspan="1" colspan="1">LDLR adaptor protein</td><td rowspan="1" colspan="1">Protein used in clathrin-mediated internalization of LDLR</td><td rowspan="1" colspan="1">Mutations lead to LDLR malfunction</td></tr><tr><td rowspan="1" colspan="1">Apo B</td><td rowspan="1" colspan="1">Apo B</td><td rowspan="1" colspan="1">It is required for LDL to bind with LDLR</td><td rowspan="1" colspan="1">Impairment in binding with LDLR</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">PCSK9</td><td rowspan="1" colspan="1">PCSK9 gain of function</td><td rowspan="1" colspan="1">PCSK9 promotes the degradation of LDLR</td><td rowspan="1" colspan="1">Elevated PCSK9 levels damage LDLRs</td></tr></tbody></table></table-wrap><p>Current treatment therapies for FH</p><p>Statins</p><p>Stains are the most important drug used in the medication of FH. It is often used with other lipid-lowering drugs. Statins are&#x000a0;routinely used as therapeutic&#x000a0;drugs reducing raised cholesterol levels. It acts mainly by inhibiting&#x000a0;the HMG-CoA (hydroxy methyl glutaryl-coenzyme A) reductase enzyme, this enzyme regulates the overall metabolism of cholesterol in the body [<xref rid="REF15" ref-type="bibr">15</xref>]. Statin blocks the active site in this enzyme. Due to the inactivation of the site, HMG-CoA is not converted into mevalonic acid as it blocks access to the substrate. Hence cholesterol formation is reduced leading to increased expression of microsomal HMG-CoA and LDL receptor expression on the hepatocyte. LDL cholesterol clearance is increased, thus lowering LDL cholesterol levels by 20-55% in circulation. Statins not only reduce LDL but also have other advantages like it decreases the chances of having dementia, reducing inflammation, improving endothelial function, and making atheromatic plaque stable&#x000a0;[<xref rid="REF16" ref-type="bibr">16</xref>]. Statin therapy leads to enhanced production of LDLR [<xref rid="REF17" ref-type="bibr">17</xref>]. Some patients in spite of being sensitive to statins may respond less to statins than other FH patients as statins may also function by reducing the formation of very low-density lipoprotein. Reduction in LDL cholesterol observed in these people is less as compared to those who have hypercholesterolemia, which is acquired [<xref rid="REF18" ref-type="bibr">18</xref>].</p><p>PCSK9 Inhibitor</p><p>PCSK9 is mostly found in the liver and is important for LDLR production as it binds to hepatocytes on the protein's surface and directs its destruction. As a result, the gene PCSK9 is normal but it is expressed in an abnormal form; this is called a gain of function mutation, which leads to the development of FH, and high levels of PCSK9 are linked to hypercholesterolemia [<xref rid="REF19" ref-type="bibr">19</xref>]. A number of PCSK9 inhibitors have been created, including monoclonal antibodies (evolocumab and alirocumab) that attach to PCSK9 in circulation, thus preventing it from collaborating with surface LDLR as well as small interfering ribonucleic acid (RNA) that block PCSK9 production within cells. Numerous increased cholesterol populations, including those with FH, have been investigated using monoclonal antibodies [<xref rid="REF20" ref-type="bibr">20</xref>].</p><p>Ezetimibe</p><p>It limits the action of a transporter called Niemann-Pick C1 like 1 (NPC1L1). It inhibits the uptake of cholesterol through diet and cholesterol secretion in bile. Reduced uptake of&#x000a0;the liver increases the low-density lipoprotein receptors these receptors utilize LDL cholesterol, hence reducing&#x000a0;LDL cholesterol levels. Statins along with ezetimibe reduce LDL&#x000a0;cholesterol levels significantly [<xref rid="REF21" ref-type="bibr">21</xref>].</p><p>Mipomersen</p><p>It&#x000a0;binds to the human ApoB mRNA's coding region and causes its breakdown. This reduces atherogenic Apo B. This Apo B contains lipoproteins like LDL and very low-density lipoprotein. It inhibits apo B lipoprotein as it is an antisense oligonucleotide. The expression of LDLR is not necessary for lowering LDL&#x000a0;cholesterol levels caused by mipomersen [<xref rid="REF22" ref-type="bibr">22</xref>]. Since mipomersen is not a strong CYP isoenzyme inhibitor it cannot be metabolized by the cytochrome system. Hence, reactions among mipomersen and statins or ezetimibe are not anticipated. It has been created as an additional therapy for FH patients, particularly for those with HoFH [<xref rid="REF23" ref-type="bibr">23</xref>].</p><p>Lomitapide</p><p>The function of the protein, microsomal triglyceride protein (MTP) is the production of LDL and chylomicrons in the hepatocytes and enterocytes [<xref rid="REF22" ref-type="bibr">22</xref>]. MTP inhibitor is a potential pharmaceutical agent for the management of raised cholesterol levels above normal value. Due to this, lomitapide, an MTP inhibitor, was created and is now authorized for the management of HoFH [<xref rid="REF24" ref-type="bibr">24</xref>].</p><p>Lipoprotein Apheresis</p><p>It is a procedure in which lipoproteins from circulation are removed and hence used in the management of FH. Lipoprotein apheresis is done when drugs are ineffective in decreasing LDL. It can be done in addition to lipid-lowering drugs. It is recommended for HoFH and critical forms of HeFH, patients with HeFH not responding to statin therapy, or for patients intolerant to therapy [<xref rid="REF25" ref-type="bibr">25</xref>].&#x000a0;</p><p>Bile Acid Sequestrants</p><p>They are used in the digestive system by binding to&#x000a0;bile constituents and it is a type of resin. They interfere with the bile component's reabsorption from the gut by interacting with them and blocking bile acid's enterohepatic circulation. Bile acid sequestrants have properties of polymeric agents. They function like resins and exchange like minerals. Bile acid sequestrants combine with bile acid for the transfer of chloride ions. Because of this binding, bile acids are cleared from the enterohepatic circulation. For restoring bile acid levels, the liver starts to synthesize bile acids from cholesterol, hence cholesterol from blood is utilized, which reduces the levels of LDL [<xref rid="REF26" ref-type="bibr">26</xref>]. Table <xref rid="TAB2" ref-type="table">2</xref> depicts various current drug therapies utilized in the treatment of FH [<xref rid="REF3" ref-type="bibr">3</xref>].</p><table-wrap position="float" id="TAB2"><label>Table 2</label><caption><title>Current drug therapies used to treat familial hypercholesterolemia </title><p>HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A; CYP3A4: cytochrome P450 3A4; PCSK9: proprotein convertase subtilisin/Kexin type 9; LDL: low density lipoprotein</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Drug</td><td rowspan="1" colspan="1">Mechanism of action</td><td rowspan="1" colspan="1">Pharmacologic effect of this drug on various systems and safety issues</td></tr><tr><td rowspan="1" colspan="1">Statins: rosuvastatin, atorvastatin, lovastatin, pravastatin &#x000a0; &#x000a0;</td><td rowspan="1" colspan="1">Competitively inhibiting the active site of HMG-CoA reductase, and restricts substrate access</td><td rowspan="1" colspan="1">Low dose in deranged renal function, Asian continent, and old patients. Minimal renal excretion CYP3A4 substrate</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">PCSK9 Inhibitor: alirocumab,&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; evolocumab&#x000a0; &#x000a0; &#x000a0;</td><td rowspan="1" colspan="1">Alirocumab, evolocumab are antibodies that binds in plasma to PCSK9, promoting degradation of the PCSK9</td><td rowspan="1" colspan="1">Injection-site reactions, generally mild, nasopharyngitis &#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Ezetimibe &#x000a0;</td><td rowspan="1" colspan="1">Ezetimibe remains on surface of brush border of small intestine, preventing cholesterol absorption &#x000a0;</td><td rowspan="1" colspan="1">Abdominal pain, diarrhea, myalgia</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Mipomersen</td><td rowspan="1" colspan="1">It binds to mRNA blocking apolipoprotein B 100 synthesis. This leads to decrease LDL synthesis</td><td rowspan="1" colspan="1">Raised hepatic fat. thrombophlebitis, weakness, nausea</td></tr><tr><td rowspan="1" colspan="1">Lomitapide</td><td rowspan="1" colspan="1">Lomitapide lowers LDL cholesterol levels by a mechanism unrelated to LDLR</td><td rowspan="1" colspan="1">Elevated hepatic fat, diarrhea, gastrointestinal disturbances. &#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Bile acid sequestrants colesevelam &#x000a0; colestipol cholestyramine</td><td rowspan="1" colspan="1">The body utilizes cholesterol to generate bile acids, so there is reduction in LDL cholesterol blood levels</td><td rowspan="1" colspan="1">It should ideally consumed with food. It has gastrointestinal side effects. It also interacts with absorption of other drugs like Interference with the absorption of other drugs.</td></tr></tbody></table></table-wrap><p>Novel treatment therapies for FH</p><p>Inclisiran</p><p>It is a&#x000a0;synthesized small interfering RNA (siRNA) with&#x000a0;long&#x000a0;action. Inclisiran is useful for lowering highly raised LDL levels in blood, it is also beneficial in the treatment of other CVDs. Inclisiran is very successful in lowering bad cholesterol levels. It binds to specific liver receptors and prevents the production of PCSK9 by doing so. This drug is sold under the trade name Leqvio [<xref rid="REF27" ref-type="bibr">27</xref>].&#x000a0;The siRNA functions as a proprotein convertase inhibitor to prevent the translation of the protein PCSK9 [<xref rid="REF15" ref-type="bibr">15</xref>]. Inclisiran use was approved in the European Union. In August 2021, NICE approved it for use by the UK's National Health Service. In the United States, it was approved for medical use in December 2021. The medication is rated as the best in its class by the American Food and Drug Administration.</p><p>Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors</p><p>It is advised for treatment of FH which is resistant to statin therapy. ANGPTL3 blockers have&#x000a0;come to light as a capable drug addition to the arsenal of cholesterol-lowering treatments. ANGPTL3 is a glycoprotein involved in metabolism and it is secreted by hepatic cells. It reduces the levels of triglycerides, LDL cholesterol, and total cholesterol by inhibiting endothelial lipase and lipoprotein lipase synthesis. ANGPTL3 gene shows loss of function mutation means it&#x02019;s a genetic lesion that results either in a decrease in its genetic activity or inhibition of synthesis [<xref rid="REF28" ref-type="bibr">28</xref>]. After thorough clinical trials, this drug was declared effective and safe for use and it was approved by the United States Food and Drug Administration (FDA). ANGPTL3 is inhibited when a monoclonal antibody targets and binds with it. For patients of HoFH aged 12 years or more, this drug is used in addition to other lipid-lowering drugs [<xref rid="REF29" ref-type="bibr">29</xref>].</p><p>Bempedoic Acid</p><p>This drug is marketed under the trade name Nexletol. The hepatic enzyme produces cholesterol. Cholesterol production is blocked by bempedoic acid [<xref rid="REF30" ref-type="bibr">30</xref>]. This enzyme is called ATP citrate lyase. The United States approved the therapeutic usage of bempedoic acid in February 2020, whereas it was approved for therapeutic usage in Europe in April 2020 [<xref rid="REF31" ref-type="bibr">31</xref>]. FDA declared bempedoic acid as a first-class drug to use in treatment therapy. European Union suggests bempedoic acid for adults with primary hypercholesterolemia, dyslipidemia, and FH. If patients are unable to reduce high levels of LDL or unable to maintain normal LDL cholesterol levels in spite of the maximum tolerable dose of statin, in such cases bempedoic acid can be added along with statins and other lipid-lowering drugs [<xref rid="REF32" ref-type="bibr">32</xref>].</p><p>Gemcabene</p><p>It is a comparatively new drug. It quickens the clearance of very low-density lipoprotein. This drug reduces hepatic apolipoprotein C-III (Apo C-III) and it lowers LDL. Gemcabene enhances HDL (high-density lipoprotein) cholesterol and reduces LDL cholesterol, and triglycerides levels in the blood [<xref rid="REF33" ref-type="bibr">33</xref>].</p><p>RNA Targeted Therapeutics</p><p>This therapy causes defects in the mechanism of the translation process and it affects the nucleic acids which code the proteins and try to regulate their action in abnormal ways [<xref rid="REF34" ref-type="bibr">34</xref>]. Some examples of RNA-targeted therapies are upregulation of mRNA, modulation of RNA splicing oligonucleotide, miRNA mimics, and inhibitors. They don't integrate into the host DNA, are synthetic and tiny, and only have a short lifespan and activity [<xref rid="REF35" ref-type="bibr">35</xref>].</p><p>DNA Targeted Therapeutics</p><p>DNA-targeted therapy typically aims to have the opposite impact as compared to RNA-targeted therapeutics. This therapy is practiced for selectively silencing and disrupting genes to show their genetic appearance. To make a mutant gene functional again, this method includes inserting functional gene copies [<xref rid="REF36" ref-type="bibr">36</xref>].</p><p>Table <xref rid="TAB3" ref-type="table">3</xref> presents an analysis of the traits and features of the articles included in the review</p><table-wrap position="float" id="TAB3"><label>Table 3</label><caption><title>Characteristics of the study included in the article</title><p>LDL: low density lipoprotein; HMG CoA:&#x000a0;&#x003b2;-hydroxy &#x003b2;-methylglutaryl-CoA; PCSK9: proprotein convertase subtilisin/Kexin type 9; Apo B: apolipoprotein B; mRNA: messenger ribonucleic acid; ATP: adenosine triphosphate; RNA: ribonucleic acid; DNA: deoxyribonucleic acid</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Author&#x000a0;</td><td rowspan="1" colspan="1">Year of publication&#x000a0;</td><td rowspan="1" colspan="1">Findings&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Tokgozoglu et al. [<xref rid="REF1" ref-type="bibr">1</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2021&#x000a0;</td><td rowspan="1" colspan="1">Findings include information regarding familial hypercholesterolemia, it is autosomal dominant genetic disease, it occurs due to increases low density lipoprotein levels and its types.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Bouhairie et al. [<xref rid="REF3" ref-type="bibr">3</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2015&#x000a0;</td><td rowspan="1" colspan="1">According to the findings familial hypercholesterolemia remains underdiagnosed and undertreated. If it is diagnosed early and treated then risk of cardiovascular disease is reduced.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Varghese et al. [<xref rid="REF4" ref-type="bibr">4</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2014&#x000a0;</td><td rowspan="1" colspan="1">Findings suggests various treatment therapies, drugs like statins, other lipid lowering drug are used in treatment of familial hypercholesterolemia.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Benito-Vicente et al. [<xref rid="REF5" ref-type="bibr">5</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2018&#x000a0;</td><td rowspan="1" colspan="1">Familial hypercholesterolemia is an autosomal genetic disorder because of a defect in lipid metabolism resulting in the early onset of cardiovascular disease.</td></tr><tr><td rowspan="1" colspan="1">Akioyamen et al. [<xref rid="REF6" ref-type="bibr">6</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2017&#x000a0;</td><td rowspan="1" colspan="1">Genes involved in familial hypercholesterolemia are low density lipoprotein receptor gene, apolipoprotein B, proprotein convertase subtilisin/kexin type 9, low density lipoprotein receptor adapter protein 1, other unidentified genes.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Brown et al. [<xref rid="REF8" ref-type="bibr">8</xref>]&#x000a0;</td><td rowspan="1" colspan="1">1974&#x000a0;</td><td rowspan="1" colspan="1">It gives information about pathogenesis of familial hypercholesterolemia.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Durrington et al. [<xref rid="REF9" ref-type="bibr">9</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2003&#x000a0;</td><td rowspan="1" colspan="1">LDL receptors are reduced or absent in familial hypercholesterolemia .&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Rador et al. [<xref rid="REF10" ref-type="bibr">10</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2003&#x000a0;</td><td rowspan="1" colspan="1">Genetic mutation leading to familial hypercholesterolemia are described in this finding.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Hobbs et al. [<xref rid="REF11" ref-type="bibr">11</xref>]&#x000a0;</td><td rowspan="1" colspan="1">1992&#x000a0;</td><td rowspan="1" colspan="1">Low density lipoprotein receptor leads to uptake utilization and breakdown of low density lipoprotein.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Vega et al. [<xref rid="REF12" ref-type="bibr">12</xref>]&#x000a0;</td><td rowspan="1" colspan="1">1986&#x000a0;</td><td rowspan="1" colspan="1">Information about apolipoprotein B and its mutation .&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Zubieliene et al. [<xref rid="REF15" ref-type="bibr">15</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2022&#x000a0;</td><td rowspan="1" colspan="1">Early diagnosis and treatment of familial hypercholesterolemia, and about drugs likestatins, ezetimibe, bile acid sequestrants, niacin, pcsk9 inhibitors ,lompitamide, mipomersin, RNA based therapeutics.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Ward et al. [<xref rid="REF16" ref-type="bibr">16</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2019&#x000a0;</td><td rowspan="1" colspan="1">Findings about statin therapy it is first line of treatment in familial hypercholesterolemia , it acts by inhibiting HMG-CoA reductase enzyme.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Feher et al. [<xref rid="REF17" ref-type="bibr">17</xref>]&#x000a0;</td><td rowspan="1" colspan="1">1993&#x000a0;</td><td rowspan="1" colspan="1">It gives information about homozygous familial hypercholesterolemia and&#x000a0; cholesterol lipid lowering drug effect of statin.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Raal et al. [<xref rid="REF18" ref-type="bibr">18</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2000&#x000a0;</td><td rowspan="1" colspan="1">Atorvastatin reduces cholesterol by inhibiting its synthesis in homozygous familial hypercholesterolemia.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Abifadel et al. [<xref rid="REF19" ref-type="bibr">19</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2003&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;PCSK9 inhibitor used in treatment of familial hypercholesterolemia.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Benn et al. [<xref rid="REF20" ref-type="bibr">20</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2010&#x000a0;</td><td rowspan="1" colspan="1">It gives information about genetic mutation in PCSK9 gene.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Cannon et al. [<xref rid="REF21" ref-type="bibr">21</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2015&#x000a0;</td><td rowspan="1" colspan="1">Management of familial hypercholesterolemia by using other lipid lowering drug along with statins. Ezetimibe drug inhibits absorption of cholesterol from diet as well as biliary cholesterol.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Crooke et al. [<xref rid="REF22" ref-type="bibr">22</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2013&#x000a0;</td><td rowspan="1" colspan="1">Mipomersin leads to destruction of ApoB mRNA by binding with it. This leads to decreased production of low density lipoprotein, very low density lipoprotein.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Geary et al. [<xref rid="REF23" ref-type="bibr">23</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2015&#x000a0;</td><td rowspan="1" colspan="1">Mipomersin drug used in treatment of familial hypercholesterolemia, which is used as antisense oligonucleotide and it acts by inhibiting apolipoprotein B.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Raal et al. [<xref rid="REF24" ref-type="bibr">24</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2010&#x000a0;</td><td rowspan="1" colspan="1">Effectiveness of mipomersin in treatment of homozygous familial hypercholesterolemia by reducing in concentration of low density lipoprotein.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Stefanutti et al. [<xref rid="REF25" ref-type="bibr">25</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2017&#x000a0;</td><td rowspan="1" colspan="1">Lipoprotein apheresis is a procedure in which certain&#x000a0; lipoproteins are eliminated from blood. It is suggested for homozygous familial hypercholesterolemia and in critical case of heterozygous familial hypercholesterolemia.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Hashim et al. [<xref rid="REF26" ref-type="bibr">26</xref>]&#x000a0;</td><td rowspan="1" colspan="1">1965&#x000a0;</td><td rowspan="1" colspan="1">Bile acid sequestrants as emerging novel therapy in treatment of familial hypercholesterolemia. Bile acids are removed from circulation and to restore their levels cholesterol is utilised this decrease blood cholesterol level.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Wright et al. [<xref rid="REF27" ref-type="bibr">27</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2021&#x000a0;</td><td rowspan="1" colspan="1">Information about inclisiran, its mechanism of action, use in treatment of familial hypercholesterolemia. It inhibits the production of PCSK 9.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Surma et al. [<xref rid="REF28" ref-type="bibr">28</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2023&#x000a0;</td><td rowspan="1" colspan="1">Angiopoietin-like protein 3 gene is mutated leading to raised cholesterol levels in blood.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Fukuhara et al. [<xref rid="REF29" ref-type="bibr">29</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2020&#x000a0;</td><td rowspan="1" colspan="1">&#x000a0;Angiopoietin-like protein 3 gene used in management of familial hypercholesterolemia.&#x000a0;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Lawrence et al. [<xref rid="REF30" ref-type="bibr">30</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2021&#x000a0;</td><td rowspan="1" colspan="1">Enzyme ATP citrate lyase is inhibited by bempedoic acid resulting in reduction of cholesterol.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Ballantyne et al. [<xref rid="REF32" ref-type="bibr">32</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2022&#x000a0;</td><td rowspan="1" colspan="1">Bempedoic acid effective drud in treatment of heterozygous familial hypercholesterolemia.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Besekar et al. [<xref rid="REF33" ref-type="bibr">33</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2023&#x000a0;</td><td rowspan="1" colspan="1">Findings suggests that gemcabene is effective anti-inflammatory drug and cholesterol lowering effect, &#x000a0;progression of fibrosis.</td></tr><tr><td rowspan="1" colspan="1">Chen et al. [<xref rid="REF34" ref-type="bibr">34</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2022&#x000a0;</td><td rowspan="1" colspan="1">Emerging novel treatment for management of familial hypercholesterolemia.</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">McClorey et al. [<xref rid="REF35" ref-type="bibr">35</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2015&#x000a0;</td><td rowspan="1" colspan="1">Information about RNA targeted therapied for treatment of familial hypercholesterolemia.&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Defesche et al. [<xref rid="REF36" ref-type="bibr">36</xref>]&#x000a0;</td><td rowspan="1" colspan="1">2017&#x000a0;</td><td rowspan="1" colspan="1">Findings include information on DNA targeted therapy in treatment of familial hypercholesterolemia&#x000a0;</td></tr></tbody></table></table-wrap></sec><sec sec-type="conclusions"><title>Conclusions</title><p>A genetically acquired condition, FH occurs due to mutated genes that code for certain proteins regulating the LDL metabolism, resulting in the early onset of CVD because of raised contact with LDL cholesterol since an early age. Despite being one of the most prevalent autosomal dominant hereditary genetic illnesses, it frequently goes underdiagnosed and untreated. To treat patients effectively, it's essential to comprehend the pathophysiology of the illness as well as the significance of cascade screening. However, various drug therapies have emerged and are currently in use to treat FH. Statins are the preferred drugs in the treatment of FH. Many people also need ezetimibe and/or PCSK9 inhibitors for effectively lowering LDL cholesterol. The major drug in managing both types of FH is statin. However, along with statins, some other drugs are also used in combination like ezetimibe, bile acid sequestrants, PCSK9 inhibitors, and others. When pharmaceutical treatment is insufficient, lipoprotein apheresis is performed. It is also required in both types of hypercholesterolemia. People suffering from HoFH can be advised mipomersen and lomitapide drugs. Future research on novel therapies to treat FH is constantly going on.</p></sec></body><back><notes><fn-group content-type="competing-interests"><fn fn-type="COI-statement"><p>The authors have declared that no competing interests exist.</p></fn></fn-group></notes><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Familial hypercholesterolemia: global burden and approaches</article-title><source>Curr Cardiol Rep</source><person-group>
<name><surname>Tokgozoglu</surname><given-names>L</given-names></name>
<name><surname>Kayikcioglu</surname><given-names>M</given-names></name>
</person-group><fpage>151</fpage><volume>23</volume><year>2021</year><pub-id pub-id-type="pmid">34480646</pub-id>
</element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="webpage"><article-title>National Human Genome Research Institute: About familial hypercholesterolemia</article-title><date-in-citation content-type="access-date">
<month>7</month>
<year>2023</year>
</date-in-citation><year>2013</year><uri xlink:href="https://www.genome.gov/Genetic-Disorders/Familial-Hypercholesterolemia">https://www.genome.gov/Genetic-Disorders/Familial-Hypercholesterolemia</uri></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Familial hypercholesterolemia</article-title><source>Cardiol Clin</source><person-group>
<name><surname>Bouhairie</surname><given-names>VE</given-names></name>
<name><surname>Goldberg</surname><given-names>AC</given-names></name>
</person-group><fpage>169</fpage><lpage>179</lpage><volume>33</volume><year>2015</year><pub-id pub-id-type="pmid">25939291</pub-id>
</element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Familial hypercholesterolemia: a review</article-title><source>Ann Pediatr Cardiol</source><person-group>
<name><surname>Varghese</surname><given-names>MJ</given-names></name>
</person-group><fpage>107</fpage><lpage>117</lpage><volume>7</volume><year>2014</year><pub-id pub-id-type="pmid">24987256</pub-id>
</element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease</article-title><source>Int J Mol Sci</source><person-group>
<name><surname>Benito-Vicente</surname><given-names>A</given-names></name>
<name><surname>Uribe</surname><given-names>KB</given-names></name>
<name><surname>Jebari</surname><given-names>S</given-names></name>
<name><surname>Galicia-Garcia</surname><given-names>U</given-names></name>
<name><surname>Ostolaza</surname><given-names>H</given-names></name>
<name><surname>Martin</surname><given-names>C</given-names></name>
</person-group><fpage>3426</fpage><volume>19</volume><year>2018</year><pub-id pub-id-type="pmid">30388787</pub-id>
</element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis</article-title><source>BMJ Open</source><person-group>
<name><surname>Akioyamen</surname><given-names>LE</given-names></name>
<name><surname>Genest</surname><given-names>J</given-names></name>
<name><surname>Shan</surname><given-names>SD</given-names></name>
<name><surname>Reel</surname><given-names>RL</given-names></name>
<name><surname>Albaum</surname><given-names>JM</given-names></name>
<name><surname>Chu</surname><given-names>A</given-names></name>
<name><surname>Tu</surname><given-names>JV</given-names></name>
</person-group><fpage>0</fpage><volume>7</volume><year>2017</year></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Preventing early cardiovascular death in patients with familial hypercholesterolemia</article-title><source>J Am Osteopath Assoc</source><date-in-citation content-type="access-date">
<month>9</month>
<year>2017</year>
</date-in-citation><person-group>
<name><surname>Repas</surname><given-names>TB</given-names></name>
<name><surname>Tanner</surname><given-names>JR</given-names></name>
</person-group><fpage>99</fpage><lpage>108</lpage><volume>114</volume><year>2014</year><uri xlink:href="https://www.degruyter.com/document/doi/10.7556/jaoa.2014.023/html.">https://www.degruyter.com/document/doi/10.7556/jaoa.2014.023/html.</uri><pub-id pub-id-type="pmid">24481802</pub-id>
</element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity</article-title><source>Proc Natl Acad Sci U S A</source><person-group>
<name><surname>Brown</surname><given-names>MS</given-names></name>
<name><surname>Goldstein</surname><given-names>JL</given-names></name>
</person-group><fpage>788</fpage><lpage>792</lpage><volume>71</volume><year>1974</year><pub-id pub-id-type="pmid">4362634</pub-id>
</element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Dyslipidaemia</article-title><source>Lancet</source><person-group>
<name><surname>Durrington</surname><given-names>P</given-names></name>
</person-group><fpage>717</fpage><lpage>731</lpage><volume>12</volume><year>2003</year></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Monogenic hypercholesterolemia: new insights in pathogenesis and treatment</article-title><source>J Clin Investig</source><person-group>
<name><surname>Rader</surname><given-names>DJ</given-names></name>
<name><surname>Cohen</surname><given-names>J</given-names></name>
<name><surname>Hobbs</surname><given-names>HH</given-names></name>
</person-group><fpage>1795</fpage><lpage>1803</lpage><volume>6</volume><year>2003</year></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Molecular genetics of the LDL receptor gene in familial hypercholesterolemia</article-title><source>Hum Mutat</source><date-in-citation content-type="access-date">
<month>8</month>
<year>2023</year>
</date-in-citation><person-group>
<name><surname>Hobbs</surname><given-names>HH</given-names></name>
<name><surname>Brown</surname><given-names>MS</given-names></name>
<name><surname>Goldstein</surname><given-names>JL</given-names></name>
</person-group><fpage>445</fpage><lpage>466</lpage><volume>1</volume><year>1992</year><pub-id pub-id-type="pmid">1301956</pub-id>
</element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia</article-title><source>J Clin Investig</source><person-group>
<name><surname>Vega</surname><given-names>GL</given-names></name>
<name><surname>Grundy</surname><given-names>SM</given-names></name>
</person-group><fpage>1410</fpage><lpage>1414</lpage><volume>5</volume><year>1986</year><uri xlink:href="https://www.jci.org/articles/view/112729">https://www.jci.org/articles/view/112729</uri></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>The proprotein convertases and their implication in sterol and/or lipid metabolism</article-title><source>Biol Chem</source><date-in-citation content-type="access-date">
<month>8</month>
<year>2023</year>
</date-in-citation><person-group>
<name><surname>Seidah</surname><given-names>NG</given-names></name>
<name><surname>Khatib</surname><given-names>AM</given-names></name>
<name><surname>Prat</surname><given-names>A</given-names></name>
</person-group><volume>387</volume><year>2006</year><uri xlink:href="https://www.degruyter.com/document/doi/10.1515/BC.2006.110/html">https://www.degruyter.com/document/doi/10.1515/BC.2006.110/html</uri></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients</article-title><source>Nutr Metab</source><date-in-citation content-type="access-date">
<month>11</month>
<year>2008</year>
</date-in-citation><person-group>
<name><surname>Khachadurian</surname><given-names>AK</given-names></name>
<name><surname>Uthman</surname><given-names>SM</given-names></name>
</person-group><fpage>132</fpage><lpage>140</lpage><volume>15</volume><year>1973</year><uri xlink:href="https://karger.com/anm/article-abstract/15/1-2/132/379573/Experiences-with-the-Homozygous-Cases-of-Familial">https://karger.com/anm/article-abstract/15/1-2/132/379573/Experiences-with-the-Homozygous-Cases-of-Familial</uri><pub-id pub-id-type="pmid">4351242</pub-id>
</element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Familial hypercholesterolemia and its current diagnostics and treatment possibilities: a literature analysis</article-title><source>Medicina (Kaunas)</source><person-group>
<name><surname>Zubielien&#x00117;</surname><given-names>K</given-names></name>
<name><surname>Valteryt&#x00117;</surname><given-names>G</given-names></name>
<name><surname>Jonaitien&#x00117;</surname><given-names>N</given-names></name>
<name><surname>&#x0017d;aliaduonyt&#x00117;</surname><given-names>D</given-names></name>
<name><surname>Zabiela</surname><given-names>V</given-names></name>
</person-group><fpage>1665</fpage><volume>58</volume><year>2022</year><pub-id pub-id-type="pmid">36422206</pub-id>
</element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>Statin toxicity</article-title><source>Circ Res</source><person-group>
<name><surname>Ward</surname><given-names>NC</given-names></name>
<name><surname>Watts</surname><given-names>GF</given-names></name>
<name><surname>Eckel</surname><given-names>RH</given-names></name>
</person-group><fpage>328</fpage><lpage>350</lpage><volume>124</volume><year>2019</year><pub-id pub-id-type="pmid">30653440</pub-id>
</element-citation></ref><ref id="REF17"><label>17</label><element-citation publication-type="journal"><article-title>Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia</article-title><source>Atherosclerosis</source><person-group>
<name><surname>Feher</surname><given-names>MD</given-names></name>
<name><surname>Webb</surname><given-names>JC</given-names></name>
<name><surname>Patel</surname><given-names>DD</given-names></name>
<name><surname>Lant</surname><given-names>AF</given-names></name>
<name><surname>Mayne</surname><given-names>PD</given-names></name>
<name><surname>Knight</surname><given-names>BL</given-names></name>
<name><surname>Soutar</surname><given-names>AK</given-names></name>
</person-group><fpage>171</fpage><lpage>180</lpage><volume>103</volume><year>1993</year><pub-id pub-id-type="pmid">8292093</pub-id>
</element-citation></ref><ref id="REF18"><label>18</label><element-citation publication-type="journal"><article-title>Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia</article-title><source>Atherosclerosis</source><person-group>
<name><surname>Raal</surname><given-names>FJ</given-names></name>
<name><surname>Pappu</surname><given-names>AS</given-names></name>
<name><surname>Illingworth</surname><given-names>DR</given-names></name>
<etal/>
</person-group><fpage>421</fpage><lpage>428</lpage><volume>2</volume><year>2000</year></element-citation></ref><ref id="REF19"><label>19</label><element-citation publication-type="journal"><article-title>Mutations in PCSK9 cause autosomal dominant hypercholesterolemia</article-title><source>Atherosclerosis</source><person-group>
<name><surname>Abifadel</surname><given-names>M</given-names></name>
<name><surname>Varret</surname><given-names>M</given-names></name>
<name><surname>Rab&#x000e8;s</surname><given-names>JP</given-names></name>
<etal/>
</person-group><fpage>154</fpage><lpage>156</lpage><volume>2</volume><year>2003</year></element-citation></ref><ref id="REF20"><label>20</label><element-citation publication-type="journal"><article-title>PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses</article-title><source>J Am Coll Cardiol</source><person-group>
<name><surname>Benn</surname><given-names>M</given-names></name>
<name><surname>Nordestgaard</surname><given-names>BG</given-names></name>
<name><surname>Grande</surname><given-names>P</given-names></name>
<name><surname>Schnohr</surname><given-names>P</given-names></name>
<name><surname>Tybjaerg-Hansen</surname><given-names>A</given-names></name>
</person-group><fpage>2833</fpage><lpage>2842</lpage><volume>55</volume><year>2010</year><pub-id pub-id-type="pmid">20579540</pub-id>
</element-citation></ref><ref id="REF21"><label>21</label><element-citation publication-type="journal"><article-title>Ezetimibe added to statin therapy after acute coronary syndromes</article-title><source>N Engl J Med</source><person-group>
<name><surname>Cannon</surname><given-names>CP</given-names></name>
<name><surname>Blazing</surname><given-names>MA</given-names></name>
<name><surname>Giugliano</surname><given-names>RP</given-names></name>
<etal/>
</person-group><fpage>2387</fpage><lpage>2397</lpage><volume>372</volume><year>2015</year><pub-id pub-id-type="pmid">26039521</pub-id>
</element-citation></ref><ref id="REF22"><label>22</label><element-citation publication-type="journal"><article-title>Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B</article-title><source>Br J Clin Pharmacol</source><person-group>
<name><surname>Crooke</surname><given-names>ST</given-names></name>
<name><surname>Geary</surname><given-names>RS</given-names></name>
</person-group><fpage>269</fpage><lpage>276</lpage><volume>76</volume><year>2013</year><pub-id pub-id-type="pmid">23013161</pub-id>
</element-citation></ref><ref id="REF23"><label>23</label><element-citation publication-type="journal"><article-title>Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(&#x000ae;)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B</article-title><source>Clin Pharmacokinet</source><person-group>
<name><surname>Geary</surname><given-names>RS</given-names></name>
<name><surname>Baker</surname><given-names>BF</given-names></name>
<name><surname>Crooke</surname><given-names>ST</given-names></name>
</person-group><fpage>133</fpage><lpage>146</lpage><volume>54</volume><year>2015</year><pub-id pub-id-type="pmid">25559341</pub-id>
</element-citation></ref><ref id="REF24"><label>24</label><element-citation publication-type="journal"><article-title>Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial</article-title><source>Lancet</source><person-group>
<name><surname>Raal</surname><given-names>FJ</given-names></name>
<name><surname>Santos</surname><given-names>RD</given-names></name>
<name><surname>Blom</surname><given-names>DJ</given-names></name>
<etal/>
</person-group><fpage>998</fpage><lpage>1006</lpage><volume>375</volume><year>2010</year><pub-id pub-id-type="pmid">20227758</pub-id>
</element-citation></ref><ref id="REF25"><label>25</label><element-citation publication-type="journal"><article-title>Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs</article-title><source>J Clin Lipidol</source><person-group>
<name><surname>Stefanutti</surname><given-names>C</given-names></name>
<name><surname>Julius</surname><given-names>U</given-names></name>
<name><surname>Watts</surname><given-names>GF</given-names></name>
<etal/>
</person-group><fpage>858</fpage><lpage>871</lpage><volume>11</volume><year>2017</year><pub-id pub-id-type="pmid">28572002</pub-id>
</element-citation></ref><ref id="REF26"><label>26</label><element-citation publication-type="journal"><article-title>Cholestyramine resin therapy for hypercholesterolemia: clinical and metabolic studies</article-title><source>JAMA</source><date-in-citation content-type="access-date">
<month>8</month>
<year>2023</year>
</date-in-citation><person-group>
<name><surname>Hashim</surname><given-names>SA</given-names></name>
<name><surname>Vanitallie</surname><given-names>TB</given-names></name>
</person-group><fpage>289</fpage><lpage>293</lpage><volume>192</volume><year>1965</year><pub-id pub-id-type="pmid">14271976</pub-id>
</element-citation></ref><ref id="REF27"><label>27</label><element-citation publication-type="journal"><article-title>Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis</article-title><source>J Am Coll Cardiol</source><person-group>
<name><surname>Wright</surname><given-names>RS</given-names></name>
<name><surname>Ray</surname><given-names>KK</given-names></name>
<name><surname>Raal</surname><given-names>FJ</given-names></name>
<etal/>
</person-group><fpage>1182</fpage><lpage>1193</lpage><volume>77</volume><year>2021</year><pub-id pub-id-type="pmid">33663735</pub-id>
</element-citation></ref><ref id="REF28"><label>28</label><element-citation publication-type="journal"><article-title>Angiopoietin-like proteins inhibitors: new horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia</article-title><source>Cardiol J</source><person-group>
<name><surname>Surma</surname><given-names>S</given-names></name>
<name><surname>Roma&#x00144;czyk</surname><given-names>M</given-names></name>
<name><surname>Filipiak</surname><given-names>KJ</given-names></name>
</person-group><fpage>131</fpage><lpage>142</lpage><volume>30</volume><year>2023</year><pub-id pub-id-type="pmid">33470417</pub-id>
</element-citation></ref><ref id="REF29"><label>29</label><element-citation publication-type="journal"><article-title>A multi-purpose Japanese phase I study in the global development of vupanorsen: randomized, placebo-controlled, single-ascending dose study in adults</article-title><source>Clin Transl Sci</source><person-group>
<name><surname>Fukuhara</surname><given-names>K</given-names></name>
<name><surname>Furihata</surname><given-names>K</given-names></name>
<name><surname>Matsuoka</surname><given-names>N</given-names></name>
<etal/>
</person-group><fpage>886</fpage><lpage>897</lpage><volume>16</volume><year>2023</year><pub-id pub-id-type="pmid">37002654</pub-id>
</element-citation></ref><ref id="REF30"><label>30</label><element-citation publication-type="journal"><article-title>Bempedoic acid (nexletol) for the treatment of hyperlipidemia and familial hypercholesterolemia</article-title><source>Am Fam Physician</source><person-group>
<name><surname>Lawrence</surname><given-names>E</given-names></name>
<name><surname>Johns</surname><given-names>T</given-names></name>
</person-group><fpage>377</fpage><lpage>378</lpage><volume>103</volume><year>2021</year><uri xlink:href="https://pubmed.ncbi.nlm.nih.gov/33719370/">https://pubmed.ncbi.nlm.nih.gov/33719370/</uri><pub-id pub-id-type="pmid">33719370</pub-id>
</element-citation></ref><ref id="REF31"><label>31</label><element-citation publication-type="webpage"><article-title>A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)</article-title><date-in-citation content-type="access-date">
<month>4</month>
<year>2023</year>
</date-in-citation><year>2020</year><uri xlink:href="https://fdaaa.trialstracker.net/trial/NCT02722408/">https://fdaaa.trialstracker.net/trial/NCT02722408/</uri></element-citation></ref><ref id="REF32"><label>32</label><element-citation publication-type="journal"><article-title>Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)</article-title><source>Am J Cardiol</source><person-group>
<name><surname>Ballantyne</surname><given-names>CM</given-names></name>
<name><surname>Banach</surname><given-names>M</given-names></name>
<name><surname>Bays</surname><given-names>HE</given-names></name>
<etal/>
</person-group><fpage>1</fpage><lpage>11</lpage><volume>174</volume><year>2022</year><pub-id pub-id-type="pmid">35483979</pub-id>
</element-citation></ref><ref id="REF33"><label>33</label><element-citation publication-type="journal"><article-title>A systematic review of the randomized controlled trials of gemcabene and its therapeutic uses</article-title><source>Cureus</source><person-group>
<name><surname>Besekar</surname><given-names>SM</given-names></name>
<name><surname>Jogdand</surname><given-names>SD</given-names></name>
<name><surname>Naqvi</surname><given-names>WM</given-names></name>
</person-group><fpage>0</fpage><volume>15</volume><year>2023</year></element-citation></ref><ref id="REF34"><label>34</label><element-citation publication-type="journal"><article-title>The promising novel therapies for familial hypercholesterolemia</article-title><source>J Clin Lab Anal</source><person-group>
<name><surname>Chen</surname><given-names>R</given-names></name>
<name><surname>Lin</surname><given-names>S</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
</person-group><fpage>0</fpage><volume>36</volume><year>2022</year></element-citation></ref><ref id="REF35"><label>35</label><element-citation publication-type="journal"><article-title>An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies</article-title><source>Curr Opin Pharmacol</source><person-group>
<name><surname>McClorey</surname><given-names>G</given-names></name>
<name><surname>Wood</surname><given-names>MJ</given-names></name>
</person-group><fpage>52</fpage><lpage>58</lpage><volume>24</volume><year>2015</year><pub-id pub-id-type="pmid">26277332</pub-id>
</element-citation></ref><ref id="REF36"><label>36</label><element-citation publication-type="journal"><article-title>Familial hypercholesterolaemia</article-title><source>Nat Rev Dis Primers</source><person-group>
<name><surname>Defesche</surname><given-names>JC</given-names></name>
<name><surname>Gidding</surname><given-names>SS</given-names></name>
<name><surname>Harada-Shiba</surname><given-names>M</given-names></name>
<name><surname>Hegele</surname><given-names>RA</given-names></name>
<name><surname>Santos</surname><given-names>RD</given-names></name>
<name><surname>Wierzbicki</surname><given-names>AS</given-names></name>
</person-group><fpage>17093</fpage><volume>3</volume><year>2017</year><pub-id pub-id-type="pmid">29219151</pub-id>
</element-citation></ref></ref-list></back></article>
